Financial Markets collage Northcote Internet Logo
transparent spacer
transparent spacer
 >   > 
transparent spacer
 
curve on page transparent spacer
Northcote Internet Ltd provide Investor Relations Webcasting. Click Here
 
transparent spacer transparent spacer transparent spacer transparent spacer
transparent spacer Home menu end curves
Newsletter
transparent spacer
transparent spacer About Us menu end curves
transparent spacer
transparent spacer Donations menu end curves
transparent spacer
transparent spacer Registrars menu end curves
transparent spacer
transparent spacer Spread Betting menu end curves
transparent spacer
transparent spacer Submit links menu end curves
transparent spacer
transparent spacer transparent spacer
transparent spacer transparent spacer transparent spacer
transparent spacer
transparent spacer
navigation curves Home navigation curves navigation curves By Index navigation curves navigation curves By Sector navigation curves navigation curves Alphabetically navigation curves navigation curves Search navigation curves navigation curves My Portfolio navigation curves
 >  > 
 
Follow northcote_b on Twitter
AstraZeneca
transparent spacer
transparent spacer
transparent spacer
Company Information
Address: Level 9 2 Kingdom Street
London
W2 6BD
Index: To continue showing the FTSE index and sector information we need a license from FTSE International Limited. Will anyone sponsor us to return this data to the site.
Tel: +44 (0)20 7604 8000 Sector:
Fax: +44 (0)20 7604 8270
E-Mail: IR@astrazeneca.com Epic:
Secretary: Adrian Kemp    
Registrar: Equiniti Ltd Updated: 15/04/2013

News from RSS Feed

Thu, 31 Jul 2014 07:00:00 +0100

AstraZeneca PLC second quarter and half year results 2014

Pascal Soriot, Chief Executive Officer, commenting on the results, said: "“We have made significant progress in the first half of the year, with visible momentum across our cardiovascular, diabetes and respiratory franchises as well as strong growth in the emerging markets. This has driven revenue growth for the second consecutive quarter and achieved a 13% increase in Core EPS in the quarter. The pace of execution of our strategy and the underlying performance of our teams give us confidence to raise 2014 guidance for the full year."

Company Overview

AstraZeneca is a global, innovation-driven biopharmaceutical business that focuses on the discovery, development and commercialisation of prescription medicines, primarily for the treatment of cardiovascular, metabolic, respiratory, inflammation, autoimmune, oncology, infection and neuroscience diseases.

 
Annual Reports
Description Report Date Published Current  
bullet point Annual Report 2012 in PDF 31/12/2012 31/01/2013 Yes  
bullet point Annual Report 2011 in PDF 31/12/2011 2/02/2012 No  
bullet point Annual Report 2010 in PDF 31/12/2010 27/01/2011 No  
bullet point Annual Report 2009 in PDF 31/12/2009 28/01/2010 No  
bullet point Annual Report 2008 in PDF 31/12/2008 29/01/2009 No  
bullet point Annual Report 2007 in PDF 31/12/2007 31/01/2008 No  
bullet point Annual Report 2006 in PDF 31/12/2006 1/02/2007 No  
bullet point Annual Report 2005 in PDF (1.92Mb) 31/12/2005 2/02/2006 No  
bullet point Annual Report 2004 in PDF (0.93Mb) 31/12/2004 27/01/2005 No  
bullet point Annual Report 2003 in PDF (0.8Mb) 31/12/2003 29/01/2004 No  
bullet point Annual Report 2002 part 1 in PDF (0.09Mb) 31/12/2002 30/01/2003 No  
bullet point Annual Report 2002 part 2 in PDF 31/12/2002 30/01/2003 No  
bullet point Annual Report 2001 part 1 in PDF (0.01Mb) 31/12/2001 31/01/2002 No  
bullet point Annual Report 2001 part 2 in PDF 31/12/2001 31/01/2002 No  
bullet point Annual Report 2000 - Part 1 in PDF (0.01Mb) 31/12/2000 7/02/2001 No  
bullet point Annual Report 2000 - Part 2 in PDF (0.02Mb) 31/12/2000 7/02/2001 No  
bullet point Annual Report 1999 - Part 1 in PDF (0.61Mb) 31/12/1999 23/02/2000 No  
bullet point Annual Report 1999 - Part 2 in PDF (0.61Mb) 31/12/1999 23/02/2000 No  
 
Interim Reports
Description Report Date Published Current  
bullet point Interim Results 2012 in PDF 30/06/2012 26/07/2012 Yes  
bullet point Interim Results 2011 figures in PDF 30/06/2011 28/07/2011 No  
bullet point Interim Results 2011 narrative in PDF 30/06/2011 28/07/2011 No  
bullet point Interim Results 2010 - Figures in PDF 30/06/2010 29/07/2010 No  
bullet point Interim Results 2010 - Narrative in PDF 30/06/2010 29/07/2010 No  
bullet point Interim Results 2009 - Figures in PDF 30/06/2009 30/07/2009 No  
bullet point Interim Results 2009 - Narrative in PDF 30/06/2009 30/07/2009 No  
bullet point Interim Results 2008 - Figures in PDF 30/06/2008 31/07/2008 No  
bullet point Interim Results 2008 - Narrative in PDF 30/06/2008 31/07/2008 No  
bullet point Interim Results 2007 - Figures in PDF 30/06/2007 26/07/2007 No  
bullet point Interim Results 2007 - Narrative in PDF 30/06/2007 26/07/2007 No  
bullet point Interim Results 2006 - Figures in PDF 30/06/2006 27/07/2006 No  
bullet point Interim Results 2006 - Narrative in PDF (0.16Mb) 30/06/2006 27/07/2006 No  
bullet point Interim Results 2005 - Figures in PDF (0.09Mb) 30/06/2005 28/07/2005 No  
bullet point Interim Results 2005 - Narrative in PDF (0.06Mb) 30/06/2005 28/07/2005 No  
bullet point Interim Results 2004 - Figures in PDF (0.11Mb) 30/06/2004 22/07/2004 No  
bullet point Interim Results 2004 - Narrative in PDF (0.14Mb) 30/06/2004 22/07/2004 No  
bullet point Interim Results 2003 - Figures in PDF (0.09Mb) 30/06/2003 24/07/2003 No  
bullet point Interim Results 2003 - Narrative in PDF (0.13Mb) 30/06/2003 24/07/2003 No  
bullet point Interim Results 2002 - Figures in PDF (0.05Mb) 30/06/2002 25/07/2002 No  
bullet point Interim Results 2002 - Narrative in PDF (0.05Mb) 30/06/2002 25/07/2002 No  
bullet point Interim Results 2001 - Figures in PDF (0.25Mb) 30/06/2001 26/07/2001 No  
bullet point Interim Results 2001 - Narrative in PDF (0.05Mb) 30/06/2001 26/07/2001 No  
bullet point Interim Results 2000 - Figures in PDF (0.05Mb) 30/06/2000 1/08/2000 No  
bullet point Interim Results 2000 - Narrative in PDF (0.04Mb) 30/06/2000 1/08/2000 No  
bullet point Interim Results 1999 - Figures in PDF (0.02Mb) 30/06/1999 3/08/1999 No  
bullet point Interim Results 1999 - Narrative in PDF (0.03Mb) 30/06/1999 3/08/1999 No  
 
Other Links
Description
bullet point Home
bullet point Site Map
bullet point Investor Relations
bullet point Events Calendar
bullet point Results Index
bullet point Press Releases
bullet point Presentations
bullet point Contacts
bullet point RSS News Feed
       
Dividend History
Type Payment Date Dividend
Interim 18/03/2013 120.5 p
Interim 10/09/2012 58.1 p
Interim 19/03/2012 123.6 p
Interim 12/09/2011 51.9 p
Interim 14/03/2011 116.7 p
Interim 13/09/2010 44.9 p
Interim 15/03/2010 105.4 p
Interim 14/09/2009 36 p
Interim 14/09/2009 0.59 c USD
Interim 14/09/2009 27.8 p
Interim 16/03/2009 104.8 p
Interim 15/09/2008 27.8 p
Interim 17/03/2008 67.7 p
Interim 17/09/2007 25.3 p
Interim 19/03/2007 63 p
Interim 18/09/2006 26.6 p
Interim 20/03/2006 51.8 p
Interim 19/09/2005 21.9 p
Interim 21/03/2005 34.3 p
Interim 20/09/2004 16 p
Interim 6/04/2004 29.4 p
Interim 6/10/2003 15.9 p
Interim 7/04/2003 28.5 p
Interim 7/10/2002 14.7 p
Interim 8/04/2002 33.2 p
Interim 5/10/2001 16.1 p
Interim 9/04/2001 32.1 p
Interim 23/10/2000 15.3 p
Interim 17/04/2000 29.1 p
Interim 25/10/1999 14.2 p

News from RSS Feed

Thu, 31 Jul 2014 07:00:00 +0100

AstraZeneca PLC second quarter and half year results 2014

Pascal Soriot, Chief Executive Officer, commenting on the results, said: "“We have made significant progress in the first half of the year, with visible momentum across our cardiovascular, diabetes and respiratory franchises as well as strong growth in the emerging markets. This has driven revenue growth for the second consecutive quarter and achieved a 13% increase in Core EPS in the quarter. The pace of execution of our strategy and the underlying performance of our teams give us confidence to raise 2014 guidance for the full year."
Wed, 30 Jul 2014 07:00:00 +0100

AstraZeneca agrees strategic transaction with Almirall in respiratory disease

AstraZeneca today announced that it has entered an agreement to transfer to the company the rights to Almirall’s respiratory franchise for an initial consideration of $875 million on completion, and up to $1.22 billion in development, launch, and sales-related milestones. AstraZeneca has also agreed to make various sales-related payments.
Wed, 30 Jul 2014 06:00:00 +0100

AstraZeneca and Kyowa Hakko Kirin partner on immuno-oncology clinical study

AstraZeneca today announced that it has entered into a clinical study collaboration with Kyowa Hakko Kirin for a Phase I/Ib immuno-oncology study that will evaluate the safety and efficacy of two separate combinations of three investigational compounds in multiple solid tumours.
Mon, 28 Jul 2014 06:01:10 +0100

AstraZeneca and Roche announce partnership to develop companion diagnostic test for AZD9291

AstraZeneca today announced it has entered into collaboration with Roche to develop a plasma-based companion diagnostic test to support AZD9291, AstraZeneca’s investigational compound in clinical development for non-small-cell lung cancer (NSCLC).
Mon, 28 Jul 2014 06:00:00 +0100

AstraZeneca and QIAGEN enter collaboration to develop diagnostic test for lung cancer patients suitable for treatment with IRESSA

AstraZeneca today announced that it has entered into a collaboration with Netherlands-based QIAGEN to develop a non-invasive diagnostic test to identify non-small cell lung cancer (NSCLC) patients who are suitable for treatment with IRESSA®.
Tue, 22 Jul 2014 06:03:57 +0100

MedImmune and Advaxis partner on immuno-oncology combination clinical trial

AstraZeneca today announced that MedImmune, its global biologics research and development arm, has entered into a clinical trial collaboration with Advaxis, Inc., a US-based biotechnology company developing cancer immunotherapies.
Fri, 18 Jul 2014 07:00:00 +0100

AstraZeneca reveals designs for new Global R&D Centre and Corporate Headquarters in Cambridge, UK

AstraZeneca today revealed the proposed designs for its new Global R&D Centre and Corporate Headquarters in Cambridge in the UK. The plans for the new facility, which will be located on the Cambridge Biomedical Campus (CBC), include designs for the Global Centre, an R&D Enabling Building and an Energy Centre.
Wed, 25 Jun 2014 22:11:25 +0100

FDA Advisory Committee votes on accelerated approval for investigational medicine olaparib

AstraZeneca today announced that the US Food and Drug Administration (FDA) Oncologic Drugs Advisory Committee (ODAC) voted 11 to 2 that current evidence from clinical studies does not support an accelerated approval for use of olaparib as a maintenance treatment for women with platinum-sensitive relapsed ovarian cancer who have the germline BRCA (gBRCA) mutation, and who are in complete or partial response to platinum-based chemotherapy.
Thu, 12 Jun 2014 22:00:30 +0100

US FDA Advisory Committee recommends no cardiovascular outcomes trial for peripherally-acting mu-opioid receptor antagonist (PAMORA) class including MOVANTIK

AstraZeneca announced today that the majority of US Food and Drug Administration (FDA) Anesthetic and Analgesic Drug Products Advisory Committee (AADPAC) members voted that the FDA should not require cardiovascular outcomes trials for the peripherally-acting mu-opioid receptor antagonist (PAMORA) class of drugs, which includes MOVANTIK™ (naloxegol oxalate), an investigational treatment for opioid-induced constipation (OIC) for patients with chronic non-cancer pain. Following a clarification of the vote, the majority of the Committee suggested continued post-approval data collection for cardiovascular safety.
To continue showing the FTSE index and sector information we need a license from FTSE International Limited. Will anyone sponsor us to return this data to the site.


transparent spacer